Oral Therapy for Thalassemia Anemia Wins FDA Approval

For people living with thalassemia, an inherited blood disorder that impairs the production of healthy red blood cells, treatment has long meant lifelong transfusions and the burdens that come with them. A new option arrived on 23 December 2025, when the US Food and Drug Administration approved mitapivat, sold as AQVESME, as an oral disease-modifying treatment for anemia in adults with alpha- or beta-thalassemia, regardless of whether they depend on transfusions.

Mitapivat is a first-in-class pill known as a pyruvate kinase activator. It works by targeting an underlying energy deficit inside red blood cells, helping them survive and function better. The approval rested on two large, randomized, double-blind, placebo-controlled Phase 3 trials. In ENERGIZE, which enrolled 194 patients who do not depend on regular transfusions, significantly more people on mitapivat achieved a meaningful rise in hemoglobin than on placebo, along with improvements in markers of red-cell breakdown and in patient-reported fatigue. In ENERGIZE-T, with 258 transfusion-dependent patients, the drug substantially reduced the volume of transfusions needed.

Because it is a once-daily oral medicine rather than an infusion or a complex procedure, mitapivat could ease day-to-day life for many patients and broaden access to disease-modifying care.

The approval comes with clear limits. The label carries a boxed warning for hepatocellular (liver) injury, and patients enrolled in a risk-management program require regular liver-function monitoring; common side effects included headache and insomnia. Mitapivat is not a cure and does not correct the genetic cause of thalassemia — it manages anemia and reduces transfusion burden. Still, having an oral, disease-modifying therapy that works across the spectrum of thalassemia marks a meaningful step forward for a condition that affects hundreds of thousands of people worldwide.